Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001, 8: 739-758. 10.1016/S1074-5521(01)00056-4.
Mitchell BS: The proteasome – an emerging therapeutic target in cancer. N Engl J Med. 2003, 348: 2597-2598. 10.1056/NEJMp030092.
Adams J: Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today. 2003, 8: 307-315. 10.1016/S1359-6446(03)02647-3.
Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, Yamamoto H, Konishi M, Oki T: Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo. 1992, 45: 1746-1752.
Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A. 1999, 96: 10403-10408. 10.1073/pnas.96.18.10403.
Ostrowska H, Wojcik C, Omura S, Worowski K: Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun. 1997, 234: 729-732. 10.1006/bbrc.1997.6434.
Mellgren RL: Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome. J Biol Chem. 1997, 272: 29899-29903. 10.1074/jbc.272.47.29899.
Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh H: Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A. 1997, 94: 6629-6634. 10.1073/pnas.94.13.6629.
Bromme D, Klaus JL, Okamoto K, Rasnick D, Palmer JT: Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem J. 1996, 315: 85-89.
Levine L: Proteolysis negatively regulates agonist-stimulated arachidonic acid metabolism. Cell Signal. 1998, 10: 653-659. 10.1016/S0898-6568(98)00008-4.
Levine L: Lactacystin stimulates arachidonic acid metabolism in rat liver cells: effects of cell density on arachidonic acid release, PGI2 production and cyclooxygenase activity. Prostaglandins Leukot Essent Fatty Acids. 2000, 63: 371-375. 10.1054/plef.2000.0230.
Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME: Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys. 2000, 374: 325-333. 10.1006/abbi.1999.1646.
Rigas A, Levine L: Arachidonic acid metabolism by rat liver cells (the C-9 cell line). J Pharmacol Exp Ther. 1984, 231: 230-235.
Levine L: Tamoxifen and the raloxifene analog LY117018: their effects on arachidonic acid release from cell in culture and on prostaglandin I2 production by rat liver cells. BMC Cancer. 2004
Smith WL: The eicosanoids and their biochemical mechanisms of action. Biochem J. 1989, 259: 315-324.
Edidin M: The state of lipid rafts: from model membranes to cells. Annu Rev Biophys Biomol Struct. 2003, 32: 257-279. 10.1146/annurev.biophys.32.110601.142439.
Levine L: Does the release of arachidonic acid from cells play a role in cancer chemoprevention?. FASEB J. 2003, 17: 800-802. 10.1096/fj.02-0906hyp.
Levine L: Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism. BMC Cancer. 2003, 3: 24-10.1186/1471-2407-3-24.
Levine L: Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells. Lipids Health Dis. 2003, 2: 1-10.1186/1476-511X-2-1.
Levine L: Nuclear receptor agonists stimulate release of arachidonic acid from rat liver cells. Prostaglandins Leukot Essent Fatty Acids. 2002, 67: 453-459. 10.1054/plef.2002.0456.
Diaz BL, Arm JP: Phospholipase A(2). Prostaglandins Leukot Essent Fatty Acids. 2003, 69: 87-97. 10.1016/S0952-3278(03)00069-3.
Praml C, Amler LC, Dihlmann S, Finke LH, Schlag P, Schwab M: Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa. Oncogene. 1998, 17: 2009-2012. 10.1038/sj.onc.1202121.
Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES: Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nature Genetics. 1997, 17: 88-91. 10.1038/ng0997-88.
MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM: The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell. 1995, 81: 957-966. 10.1016/0092-8674(95)90015-2.
Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR: Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003, 111: 1771-1782. 10.1172/JCI200316198.
Subbaramaiah K, Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003, 24: 96-102. 10.1016/S0165-6147(02)00043-3.
Jordan VC, Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev. 1999, 20: 253-278. 10.1210/er.20.3.253.
Brower V: Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst. 2003, 95: 844-846. 10.1093/jnci/95.12.844.
Brash AR.: Arachidonic acid as a bioactive molecule. J Clin Invest. 2001, 107: 1339-1345.
Laye JP, Gill JH: Phospholipase A2 expression in tumours: a target for therapeutic intervention?. Drug Discov Today. 2003, 8: 710-716. 10.1016/S1359-6446(03)02754-5.
Levine L: Stimulated release of arachidonic acid from rat liver cells by celecoxib and indomethacin. Prostaglandins Leukot Essent Fatty Acids. 2001, 65: 31-35. 10.1054/plef.2001.0284.
Levine L: Measurement of arachidonic acid metabolites by radioimmunoassay. Manual of Clinical Laboratory Immunology. Edited by: Rose NR, Friedman H, Fahey JL. 1986, Washington DC: American Society for Microbiology, 685-691. 3